Literature DB >> 28793997

Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial.

Adam P Bress1,2, Jordan B King3, Kathryn E Kreider4, Srinivasan Beddhu5, Debra L Simmons2,6, Alfred K Cheung5, Yingying Zhang7, Michael Doumas8, John Nord9, Mary Ellen Sweeney10, Addison A Taylor11, Charles Herring12, William J Kostis13, James Powell14, Anjay Rastogi15, Christianne L Roumie16, Alan Wiggers17, Jonathan S Williams18, Reem Yunis19, Athena Zias20,21, Greg W Evans22, Tom Greene7,7, Michael V Rocco23, William C Cushman24, David M Reboussin22, Mark N Feinglos25, Vasilios Papademetriou8.   

Abstract

OBJECTIVE: To determine whether the effects of intensive (<120 mmHg) compared with standard (<140 mmHg) systolic blood pressure (SBP) treatment are different among those with prediabetes versus those with fasting normoglycemia at baseline in the Systolic Blood Pressure Intervention Trial (SPRINT). RESEARCH DESIGN AND METHODS: This was a post hoc analysis of SPRINT. SPRINT participants were categorized by prediabetes status, defined as baseline fasting serum glucose ≥100 mg/dL versus those with normoglycemia (fasting serum glucose <100 mg/dL). The primary outcome was a composite of myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes. Cox regression was used to calculate hazard ratios for study outcomes with intensive compared with standard SBP treatment among those with prediabetes and normoglycemia.
RESULTS: Among 9,361 participants randomized (age 67.9 ± 9.4 years; 35.5% female), 3,898 and 5,425 had baseline prediabetes and normoglycemia, respectively. After a median follow-up of 3.26 years, the hazard ratio for the primary outcome was 0.69 (95% CI 0.53, 0.89) and 0.83 (95% CI 0.66, 1.03) among those with prediabetes and normoglycemia, respectively (P value for interaction 0.30). For all-cause mortality, the hazard ratio with intensive SBP treatment was 0.77 (95% CI 0.55, 1.06) for prediabetes and 0.71 (95% CI 0.54, 0.94) for normoglycemia (P value for interaction 0.74). Effects of intensive versus standard SBP treatment on prespecified renal outcomes and serious adverse events were similar for prediabetes and normoglycemia (all interaction P > 0.05).
CONCLUSIONS: In SPRINT, the beneficial effects of intensive SBP treatment were similar among those with prediabetes and fasting normoglycemia.
© 2017 by the American Diabetes Association.

Entities:  

Year:  2017        PMID: 28793997      PMCID: PMC5606306          DOI: 10.2337/dc17-0885

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  22 in total

1.  Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).

Authors:  Adam P Bress; Holly Kramer; Rasha Khatib; Srinivasan Beddhu; Alfred K Cheung; Rachel Hess; Vinod K Bansal; Guichan Cao; Jerry Yee; Andrew E Moran; Ramon Durazo-Arvizu; Paul Muntner; Richard S Cooper
Journal:  Circulation       Date:  2017-02-13       Impact factor: 29.690

2.  Normal fasting plasma glucose and risk of type 2 diabetes diagnosis.

Authors:  Gregory A Nichols; Teresa A Hillier; Jonathan B Brown
Journal:  Am J Med       Date:  2008-06       Impact factor: 4.965

3.  Effects of prediabetes mellitus alone or plus hypertension on subsequent occurrence of cardiovascular disease and diabetes mellitus: longitudinal study.

Authors:  Miaoyan Qiu; Weili Shen; Xiaomin Song; Liping Ju; Wenxin Tong; Haiyan Wang; Sheng Zheng; Yan Jin; Yixin Wu; Weiqing Wang; Jingyan Tian
Journal:  Hypertension       Date:  2015-01-26       Impact factor: 10.190

4.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton
Journal:  Clin Trials       Date:  2014-06-05       Impact factor: 2.486

Review 5.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Authors:  Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi
Journal:  Lancet       Date:  2015-12-24       Impact factor: 79.321

6.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

7.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

8.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

Review 9.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

Authors:  Xinfang Xie; Emily Atkins; Jicheng Lv; Alexander Bennett; Bruce Neal; Toshiharu Ninomiya; Mark Woodward; Stephen MacMahon; Fiona Turnbull; Graham S Hillis; John Chalmers; Jonathan Mant; Abdul Salam; Kazem Rahimi; Vlado Perkovic; Anthony Rodgers
Journal:  Lancet       Date:  2015-11-07       Impact factor: 79.321

10.  Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.

Authors:  Karen L Margolis; Patrick J O'Connor; Timothy M Morgan; John B Buse; Robert M Cohen; William C Cushman; Jeffrey A Cutler; Gregory W Evans; Hertzel C Gerstein; Richard H Grimm; Edward W Lipkin; K M Venkat Narayan; Matthew C Riddle; Ajay Sood; David C Goff
Journal:  Diabetes Care       Date:  2014-03-04       Impact factor: 19.112

View more
  16 in total

1.  Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events.

Authors:  Naveen Rathi; Paul K Whelton; Glenn M Chertow; William C Cushman; Alfred K Cheung; Guo Wei; Robert Boucher; Paul L Kimmel; Adam P Bress; Holly J Kramer; Catreena Al-Marji; Tom Greene; Srinivasan Beddhu
Journal:  Am J Hypertens       Date:  2019-11-15       Impact factor: 2.689

Review 2.  Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care.

Authors:  Catherine G Derington; Jordan B King; Kelsey B Bryant; Blake T McGee; Andrew E Moran; William S Weintraub; Brandon K Bellows; Adam P Bress
Journal:  Curr Hypertens Rep       Date:  2019-11-07       Impact factor: 5.369

Review 3.  Implications of Recent Clinical Trials and Hypertension Guidelines on Stroke and Future Cerebrovascular Research.

Authors:  Daniel T Lackland; Robert M Carey; Adriana B Conforto; Clive Rosendorff; Paul K Whelton; Philip B Gorelick
Journal:  Stroke       Date:  2018-02-21       Impact factor: 7.914

4.  Prediabetes and Risk for Cardiovascular Disease by Hypertension Status in Black Adults: The Jackson Heart Study.

Authors:  Demetria Hubbard; Lisandro D Colantonio; Rikki M Tanner; April P Carson; Swati Sakhuja; Byron C Jaeger; Robert M Carey; Laura P Cohen; Daichi Shimbo; Mark Butler; Alain G Bertoni; Aisha T Langford; John N Booth; Jolaade Kalinowski; Paul Muntner
Journal:  Diabetes Care       Date:  2019-10-07       Impact factor: 19.112

Review 5.  SPRINT Revisited: Updated Results and Implications.

Authors:  Jackson T Wright; Paul K Whelton; Karen C Johnson; Joni K Snyder; David M Reboussin; William C Cushman; Jeff D Williamson; Nicholas M Pajewski; Alfred K Cheung; Cora E Lewis; Suzanne Oparil; Michael V Rocco; Srinivasan Beddhu; Lawrence J Fine; Jeffrey A Cutler; Walter T Ambrosius; Mahboob Rahman; Carolyn H Still; Zhengyi Chen; Curtis Tatsuoka
Journal:  Hypertension       Date:  2021-11-10       Impact factor: 10.190

Review 6.  Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities.

Authors:  Agnieszka Przezak; Weronika Bielka; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

7.  Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus.

Authors:  Faisal Rahman; John W McEvoy; Toshiaki Ohkuma; Michel Marre; Pavel Hamet; Stephen Harrap; Giuseppe Mancia; Anthony Rodgers; Elizabeth Selvin; Bryan Williams; Paul Muntner; John Chalmers; Mark Woodward
Journal:  Hypertension       Date:  2019-06       Impact factor: 10.190

8.  Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high-normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database.

Authors:  Yan Gong; Steven M Smith; Eileen M Handberg; Carl J Pepine; Rhonda M Cooper-DeHoff
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-13       Impact factor: 3.738

9.  Cardiovascular outcomes in patients with diabetes when initiating blood pressure lowering at baseline SBP between 130 and 140 mm Hg: A meta-analysis.

Authors:  Shifei Wang; Nima Moumin Djama; Yanxian Lai; Hairui Li; Wangjun Liao; Yulin Liao; Jianping Bin
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-01-13       Impact factor: 3.738

10.  Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Ling Zhang; Xiuting Sun; Lizhen Liao; Shaozhao Zhang; Huimin Zhou; Xiangbin Zhong; Xiaodong Zhuang; Xinxue Liao
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-10-31       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.